SCM
CGEM icon

Soleus Capital Management’s Cullinan Oncology CGEM Stock Holding History

Soleus Capital Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$911K Sell
50,000
-360,200
-88% -$5.35M 0.03% 88
2026
Q1 		$5.83M Buy
+410,200
New +$5.27M 0.24% 62
2022
Q3 		– Sell
-95,485
Closed -$1.22M – 79
2022
Q2 		$1.22M Buy
+95,485
New +$1.08M 0.19% 66

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Soleus Capital Management's CGEM Position: Q2 2026 in Review

Soleus Capital Management reduced its Cullinan Oncology (CGEM) stake by 88% in Q2 2026, selling an estimated $5.35M and leaving 50,000 shares worth $911K. The position accounts for 0.03% of the portfolio, ranked #88.

Soleus Capital Management first reported a position in CGEM in Q2 2022 and has held it in 3 quarters since. The position peaked at $5.83M in Q1 2026. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Soleus Capital Management held 50,000 shares of Cullinan Oncology worth $911K as of Q2 2026.
  • Soleus Capital Management sold 360,200 Cullinan Oncology shares in Q2 2026, an estimated $5.35M.
  • Cullinan Oncology made up 0.03% of Soleus Capital Management's portfolio in Q2 2026, its #88 holding.
  • Soleus Capital Management first reported a position in Cullinan Oncology in Q2 2022 and has held it in 3 quarters since.
  • Soleus Capital Management's Cullinan Oncology position peaked at $5.83M in Q1 2026.
  • 184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.